Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Retrospective Cohort Study. [PDF]
Ophthalmol SciPan SY +9 more
europepmc +1 more source
Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2. [PDF]
Eur J NeurolHastrup S +4 more
europepmc +1 more source
Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study. [PDF]
Front Clin Diabetes HealthcHirotsu T, Taniguchi K, Nishimura R.
europepmc +1 more source
Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review. [PDF]
Clin Diabetes EndocrinolZaresharifi S +3 more
europepmc +1 more source
Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration. [PDF]
J Pharm TechnolKrishnan A, Suryanarayanan SK, Mansi IA.
europepmc +1 more source
Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies. [PDF]
Iran J Pharm ResBayanati M +5 more
europepmc +1 more source
Related searches: